Kvittingen EA, Halvorsen S, Jellum E (1983). “Deficient fumarylacetoacetate fumarylhydrolase activity in lymphocytes and fibroblasts from patients with hereditary tyrosinemia”. Pediatr. Res.17 (7): 541–4. doi:10.1203/00006450-198307000-00005. PMID6622096.
Kvittingen EA, Jellum E, Stokke O (1982). “Assay of fumarylacetoacetate fumarylhydrolase in human liver-deficient activity in a case of hereditary tyrosinemia”. Clin. Chim. Acta115 (3): 311–9. doi:10.1016/0009-8981(81)90244-8. PMID7296877.
Hahn SH, Krasnewich D, Brantly M, Kvittingen EA, Gahl WA (1995). “Heterozygosity for an exon 12 splicing mutation and a W234G missense mutation in an American child with chronic tyrosinemia type 1”. Hum. Mutat.6 (1): 66–73. doi:10.1002/humu.1380060113. PMID7550234.
St-Louis M, Poudrier J, Phaneuf D, Leclerc B, Laframboise R, Tanguay RM (1995). “Two novel mutations involved in hereditary tyrosinemia type I”. Hum. Mol. Genet.4 (2): 319–20. doi:10.1093/hmg/4.2.319. PMID7757089.
Kato S, Sekine S, Oh SW, Kim NS, Umezawa Y, Abe N, Yokoyama-Kobayashi M, Aoki T (1995). “Construction of a human full-length cDNA bank”. Gene150 (2): 243–50. doi:10.1016/0378-1119(94)90433-2. PMID7821789.
Rootwelt H, Chou J, Gahl WA, Berger R, Coşkun T, Brodtkorb E, Kvittingen EA (1994). “Two missense mutations causing tyrosinemia type 1 with presence and absence of immunoreactive fumarylacetoacetase”. Hum. Genet.93 (6): 615–9. doi:10.1007/BF00201558. PMID8005583.
Grompe M, St-Louis M, Demers SI, al-Dhalimy M, Leclerc B, Tanguay RM (1994). “A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I”. N. Engl. J. Med.331 (6): 353–7. doi:10.1056/NEJM199408113310603. PMID8028615.
St-Louis M, Leclerc B, Laine J, Salo MK, Holmberg C, Tanguay RM (1994). “Identification of a stop mutation in five Finnish patients suffering from hereditary tyrosinemia type I”. Hum. Mol. Genet.3 (1): 69–72. doi:10.1093/hmg/3.1.69. PMID8162054.
Grompe M, al-Dhalimy M (1993). “Mutations of the fumarylacetoacetate hydrolase gene in four patients with tyrosinemia, type I”. Hum. Mutat.2 (2): 85–93. doi:10.1002/humu.1380020205. PMID8318997.
Labelle Y, Phaneuf D, Leclerc B, Tanguay RM (1993). “Characterization of the human fumarylacetoacetate hydrolase gene and identification of a missense mutation abolishing enzymatic activity”. Hum. Mol. Genet.2 (7): 941–6. doi:10.1093/hmg/2.7.941. PMID8364576.
Labelle Y, Puymirat J, Tanguay RM (1993). “Localization of cells in the rat brain expressing fumarylacetoacetate hydrolase, the deficient enzyme in hereditary tyrosinemia type 1”. Biochim. Biophys. Acta1180 (3): 250–6. doi:10.1016/0925-4439(93)90046-4. PMID8422430.
Ploos van Amstel JK, Bergman AJ, van Beurden EA, Roijers JF, Peelen T, van den Berg IE, Poll-The BT, Kvittingen EA, Berger R (1996). “Hereditary tyrosinemia type 1: novel missense, nonsense and splice consensus mutations in the human fumarylacetoacetate hydrolase gene; variability of the genotype-phenotype relationship”. Hum. Genet.97 (1): 51–9. doi:10.1007/bf00218833. PMID8557261.